Hormonal approaches in the treatment of bony metastases

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Hormonal therapy for prostate cancer designed to reduce testosterone levels has been employed for decades and provides objective remission rates of 40% to 60% and subjective response rates of 60% to 85%. Orchiectomy, as well as pharmacological androgen deprivation strategies such as diethylstilbestrol (DES), luteinizing hormone-releasine hormone (LHRH) agonists, and antiandrogens all provide similar clinical responses, but there are differences in safety and tolerability. Although advances have been made, the optimization of hormonal therapy of advanced metastatic prostate cancer remains challenging. Recent trials demonstrate a clinical benefit to combination antiandrogen/LHRH agonist therapy, especially in patients with minimal disease. As promising as these results appear, hormonal manipulation eventually ends in relapse and quality of life and pain relief remain important goals that must be addressed with alternative modalities.

Original languageEnglish
Pages (from-to)9-14
Number of pages6
Issue number11 SUPPL.
StatePublished - 1994


Dive into the research topics of 'Hormonal approaches in the treatment of bony metastases'. Together they form a unique fingerprint.

Cite this